Judge Orders Teva To Delist Inhaler Patents From FDA’s Orange Book

By Maaisha Osman / June 11, 2024 at 6:16 PM
Teva Pharmaceuticals has been ordered to delist five patents on its inhaler products from FDA’s Orange Book, in a ruling from a New Jersey federal court that sides with generics manufacturer Amneal Pharmaceuticals and the Federal Trade Commission (FTC). FTC filed an amicus brief in Teva Branded Pharmaceutical Products R&D, et al. v. Amneal Pharmaceuticals of New York, LLC, et al., in March, arguing that Teva recently doubled down on its stance by recertifying its Orange Book listings, which FTC...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.